Evidence map›Paper›PMID 34235077›Full record

SynthesisFrontiers in oncology2021

Evidence on Efficacy and Safety of Chinese Medicines Combined Western Medicines Treatment for Breast Cancer With Endocrine Therapy.

Lu Li, Rongyun Wang, Aolin Zhang, Ling Wang, Qianwen Ge, Yuan Liu, Tianhui Chen, Chi Chiu Wang, Ping Chung Leung, Qiuhua Sun and 1 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Lu LiCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Rongyun WangSchool of Nursing, Zhejiang Chinese Medical University, Hangzhou, China.
Aolin ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Ling WangThe First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Qianwen GeThe First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Yuan LiuThe First College of Clinical Medicine, Lanzhou University, Lanzhou, China.
Tianhui ChenDepartment of Cancer Prevention/Experimental Research Center, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Chi Chiu WangDepartment of Obstetrics & Gyneacology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Ping Chung LeungInstitute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Qiuhua SunSchool of Nursing, Zhejiang Chinese Medical University, Hangzhou, China.
Xiaohui FanCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Zhejiang Chinese Medical University · CNChinese University of Hong Kong · CNZhejiang University · CNLanzhou University · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer, a malignant disorder, occurs in epithelial tissue of the breast glands and ducts. Endocrine therapy is commonly applied as an important adjuvant treatment for breast cancer, but it usually induces a variety of side effects. Chinese Medicines (CM) has therapeutic effect on reducing adverse effects of the endocrine therapy in many clinical studies. But strong evidence is still limited on the efficacy and safety of CM combined western medicines (CM-WM) for breast cancer.

objectiveTo study the efficacy and safety of CM-WM as an adjuvant treatment for reducing side effects induced by endocrine therapy in breast cancer patients.

methodWe searched relevant clinical studies in PubMed and the Chinese National Knowledge Infrastructure (CNKI) databases up to February 28, 2021 and only Randomized Controlled Trials (RCTs) were included. There were no limitations on the languages. We extracted data from the included RCTs, assessed study quality, conducted meta-analyses by RevMan 5.4 and compared the pooled Risk Ratios (RR) or Mean Difference (MD) with 95% CIs.

resultsIn total 28 trials involving 1,926 participants were included. Six RCTs compared CM-WM with CM placebo-WM, while 22 RCTs compared CM-WM with WM alone. No study compared CM-WM with no treatment. Meta-analysis showed that CM-WM treatment significantly improved quality of life (MD = 0.73, 95% CI = 0.11-1.35,

conclusionThe adjunctive use of CM reduced the endocrine therapy associated adverse events, including bone mineral density loss, perimenopausal symptoms, poor quality of life, pain and impaired immune function. But large-scale and high quality RCTs are needed to support the application of CM-WM therapy.

Indexed as

breast cancerChinese medicines combined western medicinesefficacyendocrine therapysafety

Identifiers

PMID34235077
PMCPMC8255804
OpenAlexW3174882475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.